Morphic announces corporate highlights and financial results for the full year 2023

Morf ends '23 with $700 million, cash into 2h27; morf-057 emerald-2 uc trial enrolling on target; to begin ph 2 garnet trial of 057 in crohn's disease 1h24
MORF Ratings Summary
MORF Quant Ranking